Assessment of HER2 Protein Overexpression and Gene Amplification in Renal Collecting Duct Carcinoma: Therapeutic Implication

Cancers
Manuela CostantiniMaria Luana Poeta

Abstract

Collecting duct carcinoma (CDC) is rare and aggressive histology of kidney cancers. Although different therapeutic approaches have been tested, the 2-year survival remains very poor. Since CDC exhibits overlapping features with urothelial carcinoma, the analysis of shared molecular alterations could provide new insights into the understanding of this rare disease and also therapeutic options. We collected 26 CDC cases, and we assessed HER2 protein expression by immunohistochemistry (IHC) and gene amplification by fluorescence in-situ hybridization (FISH) according to 2018 ASCO/CAP HER2-testing recommendations. Six out of twenty-six (23%) tumors showed HER2 positive staining. In particular, 3+ score was present in 2/6 cases (33%), 2+ in 3/6 cases (50%) and 1+ in 1/6 cases (17%). The 6 HER2+ tumors were also analyzed by FISH to assess gene copy number. One out of six CDC with IHC 3+ was also HER2 amplified, showing an average HER2 copy number ≥4.0 (10.85) and a HER2/CEP17 ratio ≥ (5.63), while the 5/6 cases were HER2 negative. Based on the 2018 ASCO/CAP guidelines overall, 2/26 CDC cases (8%) were HER2+. The present study provides evidence for testing, in future studies, HER2 to assess its clinical value as a novel target for the...Continue Reading

References

Dec 13, 2005·The New England Journal of Medicine·Herbert T Cohen, Francis J McGovern
Jun 7, 2006·The Journal of Urology·Noriaki TokudaUNKNOWN Japanese Society of Renal Cancer
Sep 19, 2008·Journal of Medical Case Reports·Hisao NakamuraYasuo Nakajima
Nov 6, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N PécuchetS Oudard
Oct 12, 2016·Journal of Pathology and Translational Medicine·Gilhyang KimKyung Chul Moon
Dec 30, 2017·Molecular and Clinical Oncology·Kosuke MizutaniTakashi Deguchi
Feb 23, 2018·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Anissa MoktefiYves Allory
May 31, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffMitchell Dowsett
Jun 23, 2018·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Xinan ShengJun Guo
Mar 14, 2019·Journal of the National Comprehensive Cancer Network : JNCCN·Michael KarassBishoy M Faltas
Jan 8, 2020·Journal of the National Comprehensive Cancer Network : JNCCN·Tianhong Li
Jan 18, 2020·International Cancer Conference Journal·Kyohei WatanabeHideaki Miyake

❮ Previous
Next ❯

Methods Mentioned

BETA
Fluorescence

Related Concepts

Related Feeds

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.